
Loading, please wait...

Loading, please wait...

India continues to battle a high tuberculosis burden according to the Global TB Report 2025. Consequently, Molecular TB Diagnostics have emerged as the new standard of care across the country. These tests offer far greater accuracy than traditional smear microscopy. Smear microscopy often missed one in two cases due to its low sensitivity. Therefore, rapid molecular platforms are now essential for early and accurate detection.
Molecular TB Diagnostics like Truenat and GeneXpert provide rapid and automated results. They detect Mycobacterium tuberculosis and identify resistance to rifampicin within two hours. India’s National Tuberculosis Elimination Programme now utilizes these tools as frontline tests. Specifically, the Truenat platform serves as a point-of-care solution in primary health centers. Furthermore, these tests are cost-effective at government facilities, costing between Rs 600 and Rs 800. Currently, about 45% of TB centers use these upfront molecular tests. However, scaling this technology to all centers remains a major priority for the government.
Traditional diagnosis typically requires a sputum sample for testing. Unfortunately, many patients, especially children and the elderly, struggle to produce sputum. New innovations from Indian firms like Molbio Diagnostics solve this issue. They utilize tongue swabs for easier sample collection while maintaining high accuracy. The World Health Organization recently recommended these near-point-of-care tests for pilot introduction. Additionally, ultra-portable digital X-rays help identify asymptomatic carriers who may not visit clinics. Artificial intelligence screens these X-rays to find potential cases instantly. Then, molecular tests confirm the final diagnosis. This combined approach significantly strengthens India’s goal to eliminate tuberculosis.
Q1: What are the benefits of molecular tests over traditional microscopy?
Molecular tests provide much higher sensitivity, detecting cases that microscopy misses. They also identify drug resistance in a single step, which is crucial for starting correct treatment immediately.
Q2: Why are tongue swabs being introduced for TB testing?
Tongue swabs are easier to collect than sputum, especially for patients who cannot cough up samples. This makes testing more accessible at the point of care and improves case finding.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


India is shifting from smear microscopy to molecular diagnostics like Truenat and tongue swabs to improve TB detection rates and tackle drug resistance....
6 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today